Hinge Health (HNGE) Financials

Hinge Health’s available financial statements show a business that has shifted from near break-even operations in 2024 to sustained profitability and stronger cash generation in 2026. However, comparisons with earlier periods require caution because several 2024 and 2025 income statement figures were restated, including an unusually large Q2 2025 loss.

Revenue growth remains the clearest strength. Q2 2026 revenue reached $212.8 million, up 16.7% from $182.3 million in Q1 2026 and 53.0% from the restated $139.1 million reported in Q2 2025. Revenue has increased from $89.8 million in Q2 2024 and $100.6 million in Q3 2024, indicating strong top-line momentum across the available periods.

Profitability has also improved substantially. Gross profit rose to $183.9 million in Q2 2026, producing an 86.4% gross margin compared with 84.6% in Q1 2026 and 81.9% in Q3 2025. Operating income increased to $40.4 million, or a 19.0% operating margin, while net income attributable to common shareholders reached $43.1 million, or $0.52 per diluted share.

Operating expenses are growing more slowly than revenue in percentage terms, although marketing remains the company’s largest expense. Q2 2026 marketing expense was $81.4 million, up from $68.8 million in Q1, while revenue grew by a larger percentage. Selling, general and administrative expense and research and development expense also increased sequentially, but total operating expenses represented 67.4% of revenue in Q2 2026 versus 67.0% in Q1.

Cash generation improved meaningfully. Operating cash flow increased to $101.4 million in Q2 2026 from $43.1 million in Q1 2026 and $82.4 million in Q3 2025. Cash and equivalents increased by $99.6 million during Q2, reaching $286.2 million, while short-term investments totaled $103.2 million. Including long-term investments, Hinge Health held approximately $474.1 million in cash and investments at quarter-end.

• Rapid revenue growth: Q2 2026 revenue increased 53% year over year and has more than doubled from Q2 2024.
• Expanding margins: Gross margin reached 86.4%, while operating margin improved to 19.0% in Q2 2026.
• Sustained profitability: The company reported $43.7 million of consolidated net income and $43.1 million attributable to common shareholders in Q2 2026, following profitable results in Q1 2026 and Q4 2025.
• Stronger operating cash flow: Operating cash flow more than doubled sequentially to $101.4 million in Q2 2026.
• Significant liquidity: Cash, short-term investments and long-term investments totaled approximately $474 million at June 30, 2026, providing financial flexibility.
• Growing deferred revenue: Current deferred revenue increased to $416.5 million from $340.8 million in Q1 2026 and $299.7 million in Q3 2025, which may support future revenue recognition if services are delivered.
• Share repurchases: Hinge Health repurchased $26.5 million of common equity in Q2 and $105.0 million in Q1, potentially supporting earnings per share and reducing share dilution.
• Investment activity is driving cash-flow volatility: Q2 investing cash flow was positive $28.6 million because investment maturities exceeded purchases, rather than because of a major operating investment or acquisition.
• Balance-sheet liquidity is concentrated in current assets: Current assets of $643.4 million exceeded current liabilities of $481.4 million, but deferred revenue accounts for most current liabilities and represents an obligation to provide future services.
• Retained earnings remain deeply negative: Retained earnings were negative $972.2 million at June 30, 2026, reflecting the company’s accumulated historical losses despite recent profitability.

The balance sheet strengthened sequentially, with total assets rising to $827.4 million from $728.8 million in Q1 2026. Total liabilities increased to $483.1 million, largely because deferred revenue rose, while total equity improved to $344.3 million. The company has limited traditional debt shown in the provided statements, but investors should distinguish deferred revenue from conventional debt because it still represents future performance obligations.

Investors should also examine the quality and durability of reported earnings. Q2 2026 operating cash flow exceeded net income by a wide margin, partly because of $19.7 million of amortization, $21.6 million of other non-cash adjustments and a $15.4 million favorable change in operating assets and liabilities. These adjustments are not necessarily problematic, but they mean reported earnings and cash flow should be evaluated separately.

Overall, the statements point to improving growth, profitability and liquidity, which are favorable developments for HNGE. The main risks are the company’s accumulated deficit, continued high marketing spending, cash outflows from share repurchases and the need to determine whether recent cash-flow strength and deferred-revenue growth can persist.